DOKTOR FALK FARMA GMBKH, PREDSTAVITELSTVO
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 308
- Registration Number
- NCT06596252
- Locations
- 🇪🇸
Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain
Different Doses of Naronapride vs. Placebo in Gastroparesis
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 320
- Registration Number
- NCT05621811
- Locations
- 🇺🇸
Dr Falk Investigational Site, Harlingen, Texas, United States
🇧🇪University of Leuven, Leuven, Belgium
Mesalazine Oral Suspension in Active Eosinophilic Esophagitis
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 5
- Registration Number
- NCT05488405
- Locations
- 🇨🇭
Universitätsspital Zürich, Zürich, Switzerland
Different Doses of ZED1227 vs. Placebo in NAFLD
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 186
- Registration Number
- NCT05305599
- Locations
- 🇩🇪
Department of Medicine, University Medical Centre, Johannes Gutenberg University Mainz, Mainz, Rheinland-Pfalz, Germany
Norursodeoxycholic Acid vs. Placebo in NASH
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 363
- Registration Number
- NCT05083390
- Locations
- 🇦🇹
Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria
norUrsodeoxycholic Acid vs Placebo in PSC
- Conditions
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 303
- Registration Number
- NCT03872921
- Locations
- 🇩🇪
Medical School Hannover, Hannover, Lower Saxonia, Germany
🇦🇹Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria
Budesonide 9 mg Capsules in Active UC
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 60
- Registration Number
- NCT02550418
- Locations
- 🇩🇪
University of Schleswig-Holstein, Lübeck, Schleswig-Holstein, Germany
Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 204
- Registration Number
- NCT02493335
- Locations
- 🇩🇪
Center for Digestive Diseases Eppendorf, Hamburg, Germany
Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 88
- Registration Number
- NCT02434029
- Locations
- 🇩🇪
Center for Digestive Diseases Eppendorf, Hamburg, Germany
Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 76
- Registration Number
- NCT02280616
- Locations
- 🇩🇪
Center for Digestive Diseases Eppendorf, Hamburg, Germany